Exhibit F

RAPHAEL NUDELMAN

RAPHAEL NUDELMAN, PH.D., ERT

Raphael has over 20 years of pharmaceutical industry experience. He has a Ph.D. in organic chemistry from the Weizmann Institute of Science in Israel, a post-doctorate at the US Air Force Research Lab in Aberdeen Proving Ground, Maryland, and another post-doctorate at Duke University Medical Center, North Carolina. In 2003 Raphael joined the Medicinal Chemistry department at Teva Pharmaceuticals.

In 2010 he established the Chemical & Computational Toxicology group in Teva, and now he is Senior Director Impurity Expert in R&D Operations. Raphael's main topics of expertise are impurity and excipient qualification in drug substances and drug products. Over the past few years he has specialized in risk assessment of nitrosamine impurities in pharmaceuticals.

RELATED SESSIONS:



DETAILS

GENOTOXIC IMPURITIES IN PHARMACEUTICALS SUMMIT 2019

GTI strategies & new methodologies: analysis, in silico & regulations. Challenges & opportunities

DAY 2: **FRIDAY, 12 APRIL 2019**

CASE STUDY: **BEST PRACTICE FOR DEALING WITH CONFLICTING COMPUTATIONAL PREDICTIONS FOR MUTAGENICITY.**

- Must we always take the conservative approach when dealing with conflicting predictions?
- When can we overrule a predictions
- Case studies showing methods to come to a consensus predictions

VIEW DETAILS

DETAILS

2ND ANNUAL GENOTOXIC IMPURITIES IN PHARMACEUTICALS SUMMIT 2021

Genotoxic Impurities in Pharmaceuticals strategies & new methodologies: analysis, in silico & regulations.

15 Jul 2021 | Virtual, | Pharma

DAY 1: **THURSDAY, 15 JULY 2021**

CASE STUDY: **SETTING LIMITS FOR NITROSAMINES THAT LACK CARCINOGENICITY DATA.**

DETAILS

3RD ANNUAL GENOTOXIC IMPURITIES IN PHARMACEUTICALS SUMMIT 2023

Genotoxic Impurities in Pharmaceuticals strategies & new methodologies: analysis, in silico & regulations.

09 Mar 2023 | Virtual, | Pharma

DAY 1: THURSDAY, 09 MARCH 2023

CASE STUDY: SETTING LIMITS FOR COMPLEX NITROSAMINES (NDSRIS)

- Differences between ICH M7 and nitrosamine guidances
- Setting AIs for NDSRIs using SAR/read-across
- Case studies - De-risking of NDSRIs of drug classes (Ca channel blockers, β-blockers, ACE inhibitors)

VIEW DETAILS

QUICK LINKS

Home

Upcoming Events

About Qepler

Contact Us

OUR POLICIES

Terms & Conditions

Privacy Policy

Cookies Policy

CONTACT US

Qepler s.r.o.

Vršovická 733/83,
100 00 Praha 10-Vršovice,
Prague, Czech Republic

IČO: 06582893 / DIČ: CZ06582893

+420 770 699 211
+420 223 558 277
info@qepler.com